First to market mechanical medical device for home dialysis

Novel patient assist device for a chronic patient population in dialysis, solving the most problematic therapy step: a manual connection of tubings.

Each day, more than 1 million such connections are performed worldwide, exposing dialysis patients to the risk of infections and incurring costs to healthcare systems.


If such a connection can be **performed by a mechanical assist patient aid** more patients can receive their therapy in a home setting as opposed to the hospital, resulting in considerable **healthcare cost reductions** worldwide.

Said chronic patient population is **growing at 2-4%** annually, driven by age, diabetes, and hypertension.

The company is founded by individuals from the ETH and the medtech industry developing medical devices to facilitate dialysis treatment. It is owned by three founders who own the intellectual property rights (patent pending) to a technology platform. The founders have developed and delivered feasibility proof with a prototype.

Currently, engineering and design work is undertaken to advance the prototype to production readiness. Human factor studies are planned and university partners are on board.

Prototype: The device is used daily, it is easy to clean and disinfect, simplifies the therapy process and runs as many steps as possible in a secluded, covered area, preventing touch contamination by the patient. It is used in combination with a sterile consumable 1-5x per day.



It has the advantages to

- 1) **Simplify therapy process**: The therapy process can be streamlined.
- Increase in access to therapy: The device can broaden the patient base eligible for peritoneal dialysis
- 3) Shorten patient training times: Because several previously manual therapy steps are concentrated within the device, training times for patients should be shorter.
- 4) Reduce peritonitis infection rate (only postlaunch!): The most critical steps is performed in a standardized, controlled manner within the device.
- 5) **Enable assisted home therapy**: The Peripal device is an important because it makes assisted peritoneal dialysis financially more viable.

There is an unmet need for such a device. Preliminary market research indicates that doctors would prescribe such a patient aid to 15%-30% of their patients, 300'000 globally.

Major sales drivers are device adoption, number of devices used by one patient in a year, sales price (might differ by geography), geographic footprint, and reimbursement.

The CEO and founder has over 15 years of management experience in the medical devices market and a valuable international network within the dialysis community.

For more information contact sandra.neumann@peripal.com